From Wikipedia, the free encyclopedia
Monoclonal antibody
Inolimomab is a
mouse
monoclonal antibody developed as an
immunosuppressive drug against
graft-versus-host disease. Its target is the
alpha chain of the
interleukin-2 receptor.
[1]
[2]
References
-
^ Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, et al. (November 2006).
"Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation. 12 (11): 1135–1141.
doi:
10.1016/j.bbmt.2006.06.010.
PMID
17085306.
-
^ Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, et al. (2007).
"Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432.
doi:
10.2165/00003088-200746050-00004.
PMC
2760126.
PMID
17465640.
|
---|
Intracellular (initiation) | |
---|
Intracellular (reception) | |
---|
Extracellular | |
---|
Unsorted | |
---|